Zobrazeno 1 - 10
of 904
pro vyhledávání: '"Bonten, M"'
Autor:
Hassoun-Kheir, N., van Werkhoven, C. H., Dunning, J., Jaenisch, T., van Beek, J., Bielicki, J., Butler, C., Francois, B., Harbarth, S., Padilla, A. C. Hernandez, Horby, P., Koopmans, M., Lee, J., Rodriguez-Baño, J., Tacconelli, E., Themistocleous, Y., van der Velden, A. W., Bonten, M., Goossens, H., de Kraker, M. E. A.
The increasing threat of emerging infectious diseases and antimicrobial resistance requires more efficient, high-quality research. Perpetual Observational Studies (POS) nested within a clinical research network can improve planning, quality and effic
Externí odkaz:
http://arxiv.org/abs/2208.03992
Autor:
Colle, L., Kloosterman, F., van Bentum-Puijk, W., Vlooswijk, J., Andremont, A., Ben Hayoun, M., Canoui, E., Chabrol, A., Gamany, N., Lafaurie, M., Lefort, A., Lepeule, R., Louis, Z., Rondinaud, E., Sadou Yayé, H., Sarfati, L., Zarrouk, V., Brossier, C., Carrez, L., Lazarevic, V., Renzi, G., von Dach, E., Cohen Percia, S., Shvartz, R., Lellouche, J., Huttner, B.D., de Lastours, V., Wassenberg, M., Maharshak, N., Mauris, A., Galperine, T., Zanichelli, V., Kapel, N., Bellanger, A., Olearo, F., Duval, X., Armand-Lefevre, L., Carmeli, Y., Bonten, M., Fantin, B., Harbarth, S.
Publikováno v:
In Clinical Microbiology and Infection July 2019 25(7):830-838
Autor:
DOHMEN, W., VAN GOMPEL, L., SCHMITT, H., LIAKOPOULOS, A., HERES, L., URLINGS, B. A., MEVIUS, D., BONTEN, M. J. M., HEEDERIK, D. J. J.
Publikováno v:
Epidemiology and Infection, 2017 Jul 01. 145(10), 2003-2010.
Externí odkaz:
https://www.jstor.org/stable/26521282
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Vaccine, 40(34), 5044-5049. ELSEVIER SCI LTD
Introduction: Real-world vaccine effectiveness (VE) estimates are essential to identify potential groups at higher risk of break-through infections and to guide policy. We assessed the VE of COVID-19 vaccination against COVID-19 hospitalization, whil
Autor:
Goligher, EC, Lawler, PR, Jensen, TP, Talisa, V, Berry, LR, Lorenzi, E, McVerry, BJ, Chang, C-CH, Leifer, E, Bradbury, C, Berger, J, Hunt, BJ, Castellucci, LA, Kornblith, LZ, Gordon, AC, McArthur, C, Webb, S, Hochman, J, Neal, MD, Zarychanski, R, Berry, S, Angus, DC, Aday, A, Ahuja, T, Al-Beidh, F, Annane, D, Arabi, YM, Aryal, D, Baumann Kreuziger, L, Beane, A, Berger, JS, Berry, SM, Bhimani, Z, Bihari, S, Billett, HH, Bond, L, Bonten, M, Bradbury, CA, Brooks, MM, Brunkhorst, F, Buxton, M, Buzgau, A, Carrier, M, Castelucci, LA, Chekuri, S, Chen, J-T, Cheng, AC, Chkhikvadze, T, Coiffard, B, Contreras, A, Costantini, TW, Cushman, M, De Brouwer, S, Derde, LPG, Detry, MA, Duggal, A, Džavík, V, Effron, MB, Eng, HF, Escobedo, J, Estcourt, LJ, Everett, BM, Farkough, ME, Fergusson, DA, Fitzgerald, M, Fowler, RA, Froess, JD, Fu, Z, Galanaud, J-P, Galen, BT, Gandotra, S, Girard, TD, Godoy, LD, Gong, MN, Goodman, AL, Goossens, H, Green, C, Greenstein, YY, Gross, PL, Guerrero, RM, Hamburg, N, Haniffa, R, Hanna, G, Hanna, N, Hedge, SM, Hendrickson, CM, Higgins, AM, Hindenburg, AA, Hite, RD, Hochman, JS, Hope, AA, Horowitz, JM, Horvat, CM, Houston, BL, Huang, DT, Hudock, K, Husain, M, Hyzy, RC, Iyer, V, Jacobson, JR, Jayakumar, D, Kahn, SR, Keller, NM, Khan, A, Kim, Y, Kim, KS, Kindzelski, A, King, AJ, Kirwan, B-A, Knudson, MM, Kornblith, AE, Krishnan, V, Kumar, A, Kutcher, ME, Laffan, MA, Lamontagne, F, Le Gal, G, Leeper, CM, Leifer, ES, Lewis, RJ, Lim, G, Lima, FG, Linstrum, K, Litton, E, Lopez-Sendon, J, Lopez-Sendon Moreno, JL, Lother, SA, Madrona, SG, Malhotra, S, Marcos Martin, M, Marshall, JC, Marten, N, Martinez, AS, Martinez, M, Mateos Garcia, E, Matthay, MA, Mavromichalis, S, McArthur, CJ, McAuley, DF, McDonald, EG, McGlothlin, A, McGuinness, SP, McQuilten, ZK, Middeldorp, S, Montgomery, SK, Moore, SC, Mouncey, PR, Murthy, S, Nair, GB, Nair, R, Nichol, AD, Nicolau, JC, Nunez-Garcia, B, Pandey, A, Park, JJ, Park, PK, Parke, RL, Parker, JC, Parnia, S, Paul, JD, Pompilio, M, Prekker, M, Quigley, JG, Reynolds, HR, Rosenson, RS, Rost, NS, Rowan, K, Santos, MO, Santos, FO, Santos, M, Satterwhite, L, Saunders, CT, Schreiber, J, Schutgens, REG, Seymour, CW, Shankar Hari, M, Sheehan, JP, Siegal, DM, Silva Jr., DG, Singhal, AB, Slutsky, AS, Solvason, D, Stanworth, SJ, Tritschler, T, Turgeon, AF, Turner, AM, Van Bentum-Puijk, W, Van de Veerdonk, FL, Van Diepen, S, Vazquez Grande, G, Wahid, L, Wareham, V, Webb, SA, Wells, B, Widmer, RJ, Wilson, JG, Yuriditsky, E, Zampieri, F, Zhong, Y
Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE coul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::82cf0d06e3a57898410a86c116bb9507
http://hdl.handle.net/10044/1/103450
http://hdl.handle.net/10044/1/103450
Autor:
Pittet, L.F., Messina, N.L., Orsini, F., Moore, C.L., Abruzzo, V., Barry, S., Bonnici, R., Bonten, M., Campbell, J., Croda, J., Dalcolmo, M., Gardiner, K., Gell, G., Germano, S., Gomes-Silva, A., Goodall, C., Gwee, A., Jamieson, T., Jardim, B., Kollmann, T.R., Lacerda, M.V.G., Lee, K.J., Lucas, M., Lynn, D.J., Manning, L., Marshall, H.S., McDonald, E., Munns, C.F., Nicholson, S., O'Connell, A., Oliveira, R.D. de, Perlen, S., Perrett, K.P., Prat-Aymerich, C., Richmond, P.C., Rodriguez-Baño, J., Santos, G. Dos, Silva, P.V. da, Teo, J.W., Villanueva, P., Warris, A., Wood, N.J., Dijkstra, H.I., Eggenhuizen, E.G.P.J., Huijs, Lucas, Moorlag, S.J.C.F.M., Netea, M.G., Pranger, Eva, Taks, E.J.M., Oever, J. ten, Heine, R. ter, Davidson, A., Curtis, N.
Publikováno v:
The New England Journal of Medicine, 388, 17, pp. 1582-1596
Item does not contain fulltext BACKGROUND: The bacille Calmette-Guérin (BCG) vaccine has immunomodulatory "off-target" effects that have been hypothesized to protect against coronavirus disease 2019 (Covid-19). METHODS: In this international, double
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69bdd6da580f2f21ee06e00e7802771f
https://doi.org/10.1056/NEJMoa2212616
https://doi.org/10.1056/NEJMoa2212616
Autor:
Dautzenberg, M. J. D., Bayjanov, J. R., Leverstein-van Hall, M. A., Muller, A. E., Gelinck, L. B. S., Jansen, C. L., Leyten, E. M. S., Ruys, T., Scharringa, J., van der Starre, R. E., Fluit, A. C., Bonten, M. J. M.
Table S1. Colistin minimum inhibitory concentrations (MIC) as determined by Vitek and Etest for 100 Enterobacter isolates. (DOCX 15 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20f2a0b98858f841751d012dfec940e4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.